Cowen Research Themes 2021 has been published. Click here to learn about the year's key investment themes. >

$460 Million

Ultragenyx

Follow-on Offering

Bookrunner, October 2020

Ultragenyx is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare diseases. Founded in 2010, Ultragenyx has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are typically no approved therapies treating the underlying disease. The Company’s strategy, which is predicated upon time- and cost-efficient drug development, enables the Company to pursue multiple programs in parallel with the goal of delivering safe and effective therapies to patients with the utmost urgency.

More Like This

Jan 2021
$144 Million
DermTech logo

Follow-on Offering

Lead Left Bookrunner

View Details
Jan 2021
$225 Million

Follow-on Offering

Bookrunner

View Details
Jan 2021
$144 Million

Follow-on Offering

Bookrunner

View Details